Effect of hepatitis G virus infection on chronic hepatitis C. 1996

E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
Shinshu University School of Medicine, Nagana-ken, Japan.

OBJECTIVE To clarify the effect of hepatitis G virus (HGV) infection on chronic hepatitis C. METHODS Retrospective study. METHODS University hospital in Matsumoto, Japan. METHODS 189 randomly selected patients with histologically proven chronic hepatitis C, including 101 patients receiving interferon-alpha. METHODS Serum levels of HGV RNA were measured by reverse-transcription polymerase chain reaction. Clinical features, including liver histologic findings, hepatitis C virus (HCV) markers, and response of HCV to interferon-alpha were compared between HGV RNA-positive and HGV RNA-negative patients. RESULTS 21 of 189 (11%) patients with chronic hepatitis C were positive for HGV RNA. On average, patients with HGV RNA were younger than those without HGV RNA (mean age +/- SD, 46.6 +/- 13.0 years and 51.7 +/- 10.7 years, respectively); other demographic and clinical features were similar. The HCV genotype and HCV RNA level were distributed similarly between patients with and those without HGV infection. Ten of 101 patients with chronic hepatitis C who received interferon-alpha were positive for HGV RNA. The rate of sustained HCV response to interferon-alpha in patients with HGV infection (30%) was similar to that in patients without HGV infection (36%). The HGV RNA level decreased during therapy in all 9 patients in whom this value was measured. However, only 2 of these patients had a sustained HGV response after discontinuation of therapy. CONCLUSIONS Patients who only had HCV infection did not differ from patients with HCV and HGV co-infection in clinical presentation, HCV RNA level, or response of HCV to interferon-alpha therapy. Thus, HGV infection had no apparent influence on the clinical or virologic course of HCV infection. Hepatitis G virus was uniformly sensitive to interferon-alpha therapy, but only a few patients had a sustained virologic response.

UI MeSH Term Description Entries
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006525 Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). Viral Hepatitis, Human,Human Viral Hepatitides,Human Viral Hepatitis,Viral Hepatitides, Human
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
March 1997, Nihon rinsho. Japanese journal of clinical medicine,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
March 1999, Digestive diseases and sciences,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
January 1999, Infection,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
October 1998, Liver,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
September 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
September 2008, Hepatology international,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
March 1997, Nihon rinsho. Japanese journal of clinical medicine,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
February 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
September 2003, Annals of internal medicine,
E Tanaka, and H J Alter, and Y Nakatsuji, and J W Shih, and J P Kim, and A Matsumoto, and M Kobayashi, and K Kiyosawa
January 2004, Anales del sistema sanitario de Navarra,
Copied contents to your clipboard!